BioPorto – executive interview

BioPorto – executive interview

BioPorto Diagnostics — 2 videos in collection

BioPorto is a Denmark-based in vitro diagnostics company that uses antibody and assay expertise to transform novel research tools into clinically actionable biomarkers. The company’s portfolio includes The NGAL Test for the prediction of acute kidney injury and an extensive antibody library.

In this video, Peter Eriksen, BioPorto’s chief executive officer, highlights the company’s year-end earnings results and discusses the status of its resubmission timeline to the FDA for pediatric The NGAL Test. He also provides an update on the corporate outlook for 2021 and reviews a new vision for the product portfolio with a focus on expanding BioPorto’s proprietary gRAD technology.


You may also be interested in these:

Healthcare

Bioporto – Edison Open House interview

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.